Back to Farallon Capital Management, L.L.C. Farallon Capital Management, L.L.C.

PTGXPTGX

Showing 8 of 31 quarters

Position history for Farallon Capital Management, L.L.C.Farallon Capital Management, L.L.C.'s holdings in Protagonist Therapeutics, Inc.

Yes. Farallon Capital Management holds 6,348,906 shares of PTGX, worth $778.2M, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. Farallon Capital Management has held PTGX in every 13F on record since Q4 2018, 31 quarterly filings. PTGX is 3.6% of Farallon Capital Management's reported 13F portfolio.

Current Value

$778.2M

Current Shares

6.3M

Total Value Change

+$514.5M

Total Shares Change

+487,900

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
6.3M
0.0%
$778.2M3.6%$122.58
0
2026-Q1
Increased
6.3M
+3.3%
$669.2M3.5%$105.40
60
2025-Q4
Decreased
6.1M
-0.8%
$536.6M2.3%$87.34
0
2025-Q3
Increased
6.2M
+0.4%
$411.6M1.7%$66.43
49
2025-Q2
Increased
6.2M
+1.1%
$341.1M1.4%$55.27
49
2025-Q1
Increased
6.1M
+3.0%
$295.3M1.4%$48.36
50
2024-Q4
Increased
5.9M
+1.2%
$228.9M1.0%$38.60
49
2024-Q3
Increased
5.9M
+0.3%
$263.7M1.2%$45.00
49

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used